Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study - PubMed
2 hours ago
- #JAK inhibitors
- #Real-world study
- #Rheumatoid arthritis
- The study evaluated real-world treatment maintenance, effectiveness, and safety of four JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) in rheumatoid arthritis.
- Overall treatment maintenance was 73% at 12 months, 62% at 24 months, and 57% at 36 months, with baricitinib showing highest long-term persistence.
- All JAK inhibitors significantly improved disease activity, with reductions in DAS28-CRP of -1.57 at 6 months and -1.13 at 12 months.
- Discontinuations occurred mainly due to inefficacy (57%) and intolerance (35%), with serious adverse events like pulmonary embolism and myocardial infarction in high-risk patients before PRAC recommendations.
- After PRAC recommendations (October 2022), patient selection changed, excluding high cardiovascular risk profiles, and no major cardiovascular events occurred post-PRAC.